PMID: 7033825Jan 1, 1982Paper

Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study

Neurology
P LewittD B Calne

Abstract

Twenty-eight parkinsonian patients were studied in a double-blind, crossover comparison of lisuride and bromocriptine. All but two patients completed the study, with each drug adjusted to an optimal dose (mean daily intake of 4.5 mg for lisuride and 56.5 mg for bromocriptine). Treatment with each drug was given for 7 to 10 weeks; three assessments were made at biweekly intervals with optimal dose levels. Conventional antiparkinsonian medications, including levodopa, were not changed. Efficacy and adverse effects were assessed by objective and subjective techniques. The only significant difference was slightly better control of akinesia with bromocriptine. There was considerable variability in the optimal dose of each drug, though the clinical profile of lisuride was quite similar to that of bromocriptine.

Citations

Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·J L MontastrucM Malbezin
May 1, 1983·Journal of the Neurological Sciences·L FrattolaM Trabucchi
Sep 30, 1993·The New England Journal of Medicine·D B Calne
Oct 5, 2001·Clinical Neuropharmacology·E K Tan, J Jankovic
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
Dec 1, 1992·Acta Neurologica Scandinavica·A LaihinenI Suchy
Oct 12, 2010·CNS Drugs·Santiago Perez-Lloret, Olivier Rascol
Jun 1, 1992·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·J GinsburgM Thomas
Feb 1, 1989·British Journal of Clinical Pharmacology·M R Al-Sereiti, P Turner
May 12, 2005·Clinical Neurology and Neurosurgery·Stéphane ThoboisPascal Derkinderen
Jul 1, 1991·Journal of the American Geriatrics Society·J L Cummings
Sep 11, 2009·Journal of the Neurological Sciences·Tjalf Ziemssen, Heinz Reichmann
Jan 1, 1983·Annals of Neurology·A N LiebermanE Hiesiger
Nov 1, 2003·Expert Review of Neurotherapeutics·Eng-King Tan
Jan 1, 1986·Movement Disorders : Official Journal of the Movement Disorder Society·V MuradasJ G de Yebenes
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Jan 1, 1984·Annals of the New York Academy of Sciences·U Traugott, C S Raine
Apr 1, 1988·Acta Neurologica Scandinavica·P GiovanniniT Caraceni
Nov 25, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·P G WasielewskiW C Koller
Jun 24, 2000·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·W H Jost
Aug 1, 1987·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A E Lang
May 5, 2000·The Cochrane Database of Systematic Reviews·C E Clarke, J M Speller
Mar 5, 2003·Acta Neurologica Scandinavica·E K TanM C Wong

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.